Insulet (PODD) Cost of Revenue (2010 - 2026)

Insulet (PODD) has reported Cost of Revenue for 17 consecutive years, with $239.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 21.43% year-over-year to $239.1 million; the trailing twelve-month figure through Jun 2026 stood at $883.2 million (up 27.96% YoY), and the FY2025 full-year result was $768.2 million, up 22.74% from the prior year.
• Cost of Revenue climbed to $239.1 million in Q2 2026 per PODD's latest filing, from $232.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $239.1 million in Q2 2026 and bottomed at $85.7 million in Q1 2022.
• Historically, Cost of Revenue has averaged $161.3 million across 5 years, with a median of $155.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 75.49% in 2022, then declined 8.59% in 2023.
• Over 5 years, Cost of Revenue stood at $152.4 million in 2022, then retreated by 2.49% to $148.6 million in 2023, then climbed by 12.11% to $166.6 million in 2024, then grew by 29.17% to $215.2 million in 2025, then rose by 11.11% to $239.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $239.1 million, $232.7 million, and $215.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.